NCT03181308View on ClinicalTrials.gov

Study of Carotuximab (TRC105) Plus Nivolumab in Patients With Metastatic NSCLC

PHASE1CompletedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

November 9, 2017

Primary Completion Date

July 22, 2019

Study Completion Date

July 22, 2019

Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
DRUG

Carotuximab (TRC105)

Anti Endoglin Antibody

DRUG

OPDIVO

Programmed Death Receptor-1

Trial Locations (2)

33612

Moffitt Cancer Center, Tampa

35294

University of Alabama, Birmingham, Birmingham

All Listed Sponsors
lead

Tracon Pharmaceuticals Inc.

INDUSTRY

NCT03181308 - Study of Carotuximab (TRC105) Plus Nivolumab in Patients With Metastatic NSCLC | Biotech Hunter | Biotech Hunter